AAV and LV production, the new era with VirusGEN

Cell and gene therapy clinical trials and potential commercialization manufacturing require multiple, efficient viral vector production platforms at large-scale in a variety of cell culture platforms. Transient transfection can address this need while obtaining maximum yields and reducing costs. Mirus developed an advanced and versatile transfection formulation, “TransIT-VirusGEN". This novel technology is specifically designed for large-scale virus production to support the biopharmaceutical market’s need for highly efficient recombinant AAV and LV titers. This innovative system increases viral titers 2-10-fold over current technologies with complementary enhancers that provide better viral vector yields. Here, we highlight the benefits associated with using VirusGEN^® like i) higher titers, ii) better quality vectors (i.e., better AAV percent full capsids), iii) compatibility with various cell culture adherent and suspension systems, iv) adaptability with a turnkey easy-to-follow workflow for scalability, and v) availability in a different configuration, permitting a seamless transition from process development to GMP.

For more information, please contact us at webinar@avantorsciences.com